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Clinical Efficacy of Sildenafil
in Primary Pulmonary Hypertension
In the report entitled “Clinical Efficacy of Sildenafil in Primary
Pulmonary Hypertension: A Randomized, Placebo-Controlled,
Double-Blind, Crossover Study” (1) the investigators cite an
impressive short-term improvement in exercise capacity in patients
with pulmonary arterial hypertension (PPH) and who are taking
daily oral sildenafil. The researchers compare their patients’ im-
provement in exercise capacity with sildenafil to that of prior
studies of oral bosentan, oral beraprost, and aerosolized iloprost.
Although their earlier uncontrolled study, which used 6-min walk
testing, suggested an improvement in walk distance of 40% over
baseline (2), their more recent placebo-controlled study, which
used submaximal exercise duration on a treadmill, showed a 44%
increase in exercise time. This improvement was favorably com-
pared to bosentan, beraprost, and iloprost, whose improvement in
6-min walk distance ranged from only 12% to 21%.
We applaud the investigators’ choice of measuring exercise
endurance over a 6-min walk distance as a measure of exercise
capacity end point for patients with PPH. However, we believe
that these comparisons of sildenafil with other pulmonary vascular
drugs should be interpreted cautiously, because: 1) the patient
population in each study was not the same and 2) the 6-min walk
distance and treadmill exercise endurance times are not comparable
in terms of percent change. Oga et al. (3) have shown that
submaximal exercise endurance time is a much more sensitive
indicator of change in exercise capacity than the 6-min walk
distance or peak VO2. In that study, a 19% increase in exercise
duration paralleled a much smaller, although significant, 1%
increase in 6-min walk distance after treatment of chronic obstruc-
tive pulmonary disease patients with an inhaled anticholinergic
agent.
In measuring exercise capacity, the percent improvement in
endurance time likely depends on the level of exercise, particularly
with respect to the chosen exercise protocol (constant vs. incre-
mental work rate protocol). Thus, in this latest sildenafil study, the
44% increase in exercise duration probably overestimates the
improvement that would have been seen had the 6-min walk
distance been used to measure exercise capacity.
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REPLY
We appreciate the interest of Drs. Oudiz and Wasserman in our
study (1). Our primary objective was to compare sildenafil with
placebo in improving the exercise capacity in patients with primary
pulmonary hypertension. From this study, we did not mean to
conclude that sildenafil is superior to other pulmonary vasodilators
like bosentan; beraprost, iloprost, and others.
Improvement in exercise capacity can be measured by different
means including 6-min walk distance, submaximal exercise time,
and maximum oxygen uptake during exercise (VO2 max). These
tests measure different physiological parameters. In a group of
patients treated by the same intervention, different tests may
demonstrate different degrees of improvement depending upon the
method chosen. Even different exercise protocols may give differ-
ent results. As was pointed out, nearly 40% improvement in
exercise time using the Naughton protocol need not result in
similar degree of improvement in 6-min walk distance. Interest-
ingly, however, apart from our initial study, other investigators also
have reported a similar degree of improvement (ranging from 30%
to 50%) in 6-min walk distance with sildenafil in pulmonary
hypertension patients (2–5). It is possible that the exercise on
treadmill test using the Naughton protocol may give similar results
to the 6-min walk test, unlike the kind of exercise protocol used by
Oga et al. (6) in their studies.
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